Prevalence of Erectile Dysfunction in Male Cancer Survivors: a Systematic Review and Meta-Analysis of Cross-Sectional Studies

Pizzol, Damiano and Xiao, Tao and Smith, Lee and López Sánchez, Guillermo F. and Garolla, Andrea and Parris, Christopher N. and Barnett, Yvonne A. and Ilie, Cristian and Soysal, Pinar and Shin, Jae Il and Tully, Mark A. and Yang, Lin and Veronese, Nicola and Grabovac, Igor (2020) Prevalence of Erectile Dysfunction in Male Cancer Survivors: a Systematic Review and Meta-Analysis of Cross-Sectional Studies. British Journal of General Practice. ISSN 1478-5242

Published Version
Available under the following license: Creative Commons Attribution.

Download (1MB) | Preview
[img] Text
Accepted Version
Restricted to Repository staff only
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (306kB) | Request a copy
Official URL:


Background: Sexual function is a fundamental aspect of health, well being and quality of life. In oncological male patients sexuality and erectile dysfunction (ED) can be compromise by psychological, pharmacological or physical components. Aim: We conducted a meta-analysis to estimate the prevalence of ED in all types of cancer and identify characteristics associated with ED in cancer survivors. Design and Setting: Systematic review and meta-analysis of cross-sectional studies. Method: Random effects models were used to pool the prevalence of ED as absolute estimates at three different stages (i.e., healthy, at diagnosis, and after treatment stages). A univariate meta-analysis (MA) regression including the three-level group variable as the only independent variable was used to assess the difference of prevalence of ED across the three groups. Further MA were conducted for studies involving patients at diagnosis and after treatment. Graphical comparisons of the prevalence of ED across these two stages of cancer treatment were given by a classic forest plot. Results: We included 43 studies with a total of 19,329 participants. Overall the pooled data of the included studies showed an ED prevalence of 40.72% (95%CI: 31.80-50.29) in cancer patients, with prevalence of 28.60% (95%CI: 12.10%-53.83%) at time of diagnosis and 42.70% (95%CI: 32.97%-53.03%) after treatment, across cancer locations. Conclusion: ED is particularly high in oncologic patients and may be influenced by neurovascular damage associated with treatment, hormonal therapy systemic chemo- or radiation therapy, as well as by psychological factors such as depression, anxiety, low self-esteem or issues with body image.

Item Type: Journal Article
Keywords: Erectile Dysfunction, Cancer, Meta-analyses, Research methods, Epidemiology, Health promotion and prevention, Health promotion
Faculty: Faculty of Science & Engineering
SWORD Depositor: Symplectic User
Depositing User: Symplectic User
Date Deposited: 22 Sep 2020 11:30
Last Modified: 09 Sep 2021 18:52

Actions (login required)

Edit Item Edit Item